Research

Energy balance

The safety of retatrutide needs to be determined in larger and longer trials.

Practitioners should be aware that more extensive safety data is needed before fully endorsing retatrutide.

StrongSupportsmedium confidence
The safety of retatrutide needs to be determined in larger and longer trials.
Sheila A Doggrell · Expert Opinion on Investigational Drugs · 2023

Why this rating

Based on the phase 1b clinical trial design mentioned in the abstract.

Source

Is retatrutide (LY3437943), a GLP-1, GIP, and glucagon receptor agonist a step forward in the treatment of diabetes and obesity?

Sheila A Doggrell · Expert Opinion on Investigational Drugs · 2023

DOI 10.1080/13543784.2023.2206560

otherCited 30×
Read the paper
DOI resolved against Crossref · corpus check 2026-06-10

This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →